About the Company
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IBRX News
Why Immunitybio Inc’s (IBRX) Stock Is Up 43.84%
Immunitybio Inc’s IBRX share price has surged by 43.84%, which has investors questioning if this is right time to sell.
What's Going On With ImmunityBio Stock?
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its ...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.40%
U.S. stocks were higher after the close on Friday, as gains in the Technology, Consumer Services and Telecoms sectors led ...
ImmunityBio Inc (IBRX) Stock: What the Analysts are Saying
To sum up, ImmunityBio Inc (IBRX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that ...
Health News Roundup: US FDA approves ImmunityBio's bladder cancer therapy; US CDC warns of harmful reactions to fake Botox injections and more
However, the company forecast a low single-digit percentage decline in its 2024 adjusted core revenue, as it expects the ...
Loading the latest forecasts...